演題詳細

ポスター / Poster

ポスター 36 (Poster 36) :骨髄腫:その他

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
池田 宇次 (Takashi Ikeda):1
1:静岡県立静岡がんセンター 血液・幹細胞移植科
 
前へ戻る

Four cases of primary plasma cell leukemia

演題番号 : PS-1-273

南 次郎 (Jiro Minami):1、大内 彩 (Aya Ouchi):2、武井 豊 (Yutaka Takei):1,2、山口 祐子 (Yuko Yamaguchi):1,2、斎藤 健 (Takeshi Saito):2、大場 理恵 (Rie Ohba):1,2、横山 洋紀 (Hiroki Yokoyama):2、棚岡 さやか (Sayaka Tanaoka):1,2、土橋 史明 (Nobuaki Dobashi):1,2、薄井 紀子 (Noriko Usui):1,2、相羽 惠介 (Keisuke Aiba):2

1:Dept. Clin. Oncol. Hematol., Jikei Univ. Daisan Hospital, Tokyo, Japan、2:Dept. Clinical Oncol. Hematol., Jikei Univ. Med., Tokyo, Japan

 

[Background] Primary plasma cell leukemia (pPCL) is a rare plasma cell disorder with a poor prognosis and distinct biologic features. Novel agents like bortezomib have improved survival of multiple myeloma patients. However, datas regarding the therapeutic effects of novel agents to pPCL patients are limited. Here we present 4 cases of PCL with high risk cytogenetics. [Patients and Methods] Case 1: A 71 years old female with pPCL (IgGλ) received 4 cycles of bortezomib and dexamethasone (BD). Although PR was obtained, the disease progressed after 6 cycles of BD, she died 13 months after diagnosis. Case 2: A 59 years old female with pPCL (IgGκ) was achieved PR after 3 cycles of VAD and additional BD. The disease was progressed 12 months after diagnosis. Reduced intensity stem cell transplantation (RIST) was performed after 1 cycle of Hyper CVAD. In spite of obtaining PR after RIST, she died 18 months after diagnosis (Day 66 after RIST) because of pneumonia. Case 3: A 70 years old male with pPCL (IgGκ) achieved CR after 3 cycles of BD, but the disease progressed after 4 cycles of BD and he died after 3 months from diagnosis. CNS invasion was confirmed by autopsy. Case 4: A 62 years old female with pPCL (BJPλ) received hemodialysis due to renal failure. She received high dose dexamethasone and low dose lenalidomide, but she died 1 month diagnosis due to disease progression. [Conclusion] Our results indicated that the chemotherapy including bortezomib for pPCL was effective but not durable. The development of a novel treatment for pPCL is still required.

前へ戻る